Clinical Trials

ZW25 (Anti-HER2 x HER2 Bispecific Antibody)

ZW25 is a bispecific HER2-targeting antibody therapeutic for the treatment of patients with HER2-expressing cancers, currently being evaluated in a Phase 1 clinical trial.

Study Title: Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers

Start Date: September 2016

For more details regarding this trial, including eligibility criteria, please visit clinicaltrials.gov.